Jeito Capital said it invested in Callio Therapeutics’ $187M Series A round to support its next-generation multi-payload antibody-drug conjugates (ADCs) for cancer treatment. Callio Therapeutics ...

Jeito Capital co-leads the oversubscribed €78 million financing in Augustine Therapeutics to develop novel therapies for neuromuscular, cardio-metabolic and neurodegenerative diseases Proceeds ...

Leading the latest round of investment in XyloCor was Jeito Capital, a private equity firm based in Paris. Previous institutional investors EQT, Fountain Healthcare Partners, and Lumira Ventures ...

Frazier Life Sciences led the financing round with substantial contributions from Jeito Capital and other investors including Omega Funds, Novo Holdings, ClavystBio and Pureos Bioventures.

Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round Novo Holdings and Jeito Capital co-led the deal, supported by Asabys Partners and existing ...

The Series C, led by Jeito Capital, Novo Holdings, and RA Capital Management, will be used to support phase 1 and 2 development of Alentis’ anti-Claudin-1 antibodies for organ fibrosis and CLDN1 ...

Private equity company Jeito Capital said it is co-leading an oversubscribed €77.7 million (USD 84.8 million) Series A financing round in Augustine Therapeutics. The founding will support Phase ...

Novo Holdings and Jeito Capital co-led the deal, supported by Asabys Partners and existing investors Proceeds to support the clinical development of lead candidate AGT-100216 for the treatment of ...

Novo Holdings and Jeito Capital co-led the deal, supported by Asabys Partners and existing investors Proceeds to support the clinical development of lead candidate AGT-100216 for the treatment of ...